Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

IMS 2026 | Advances in myeloma treatment: quadruplets, CAR T-cell therapy and bispecific antibodies

Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses advances in the treatment of multiple myeloma. Dr Cerchione highlights the growing role of quadruplet regimens, including findings from PERSEUS (NCT03710603), IMROZ (NCT03319667), and CEPHEUS (NCT03652064), and the potential of sustained measurable residual disease (MRD) negativity to guide treatment discontinuation. He also explores emerging CAR T-cell therapies and bispecific antibodies, and belantamab mafodotin-based combinations following the DREAMM-7 (NCT04246047) and DREAMM-8 (NCT04484623) trials. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

The revolution in multiple myeloma is continuing, starting from the frontline setting where quadruplets became standard of care in both transplant-eligible and ineligible. We know that in transplant-eligible we have a double opportunity with the PERSEUS Dara-VRd and the IMROZ Isa-VRd that are in some way the novel opportunities in order to obtain the deepest response and sustain the MRD negativity that can correlate in next future with the cure of disease and also with the stop of the drugs in the idea to get the patient free from drugs and hospital that was till now a dream...

The revolution in multiple myeloma is continuing, starting from the frontline setting where quadruplets became standard of care in both transplant-eligible and ineligible. We know that in transplant-eligible we have a double opportunity with the PERSEUS Dara-VRd and the IMROZ Isa-VRd that are in some way the novel opportunities in order to obtain the deepest response and sustain the MRD negativity that can correlate in next future with the cure of disease and also with the stop of the drugs in the idea to get the patient free from drugs and hospital that was till now a dream. In transplant-eligible population we have CEPHEUS and IMROZ that are VRd and these are VRd. CEPHEUS also transplant-deferred population has been explored so we can also cover the unmet medical need of the gray zone and also in this case quadruplets are becoming a standard of care apart from ultra-frail patients in which a triplet could continue to have a space. Why quadruplet also transplant-ineligible? Because of the deepest response, the idea of a so long, solid response could be, maybe in the next future, the treatment for the life. So one treatment for the whole life of an elderly patient. In a relapsed/refractory setting, we know that there is a continuous revolution starting from CAR-T and bispecific antibodies. We have seen that CAR-T could now consider for young and fit patients the standard of care according to CARTITUDE-4 starting from second-line. We are better understanding which can be the best old and abridged therapies. This is a medical need that we are trying to cover. Let’s not forget data from MajesTEC-9 in which teclistamab can be placed starting from first relapse. For other patients, anti-CD38-naïve, we continue to have the Dara- and Isa-VRd-based combinations that are in some way something that can optimize the results, that can give incredible outstanding results in patients that have never tested anti-CD38 antibodies. Let’s not forget some domestic opportunities such as selinexor plus VRd and selinexor monotherapy and ixazomib, an oral proteasome inhibitor. Ixa-Len-Dex is a good triplet that in some patients can have a role, particularly in the ones that have a not favorable logistic and can be treated in the domestic setting. In ultra-treated, we have both talquetamab, elranatamab, and linvoseltamab is coming as monotherapy. Also, the combination is going to be explored and I hope to be approved as soon as possible. For patients in which we want to switch totally to a new mechanism of action, melflufen can be a solution. This is a new concept of chemotherapy that in some patients can be potentially bridging to other therapies or in the patient that we consider immunorefractory and chemosensitive can be a game changer. Other bispecific antibodies such as talquetamab, can be used in particular settings or in the idea of a tandem. Technique of talquetamab can be also a solid opportunity. I think that these new bispecific antibodies can be also a solution to drive to new CAR-T, potentially, and a bridge to the CAR-T that we had to use. We strongly wait for results from arlo-cel and from other trials.  And let’s not forget that belantamab has come back with both the solution, both the triplet, Bela-Vd and Bela-Pom-Dex, according to DREAMM-7 and DREAMM-8. Belantamab is antibody-drug conjugate. Wonderful efficacy, incredible tolerability. And I think that the placing of belantamab in our daily practice is another game changer for all the populations. We should understand if there is a room for the idea of placing in sequence more anti-BCMA agents, such as Bela-bispecific antibodies and CAR-T. This is another unmet medical need that we need to cover. However, the best has to come, and I think that the profiling of our patients in terms of molecular evaluation, the idea of biomarkers’ development can be something that helps us to drive the treatment in the idea of one drug for one patient or one combination for one patient. So the future maybe will go in the idea of targeted therapy, particularly the replacement of new drugs, such as also CELMoDs that are arriving in some way. Mezigdomide, carfilzomib, dexamethasone, can be another very good solution. Many drugs are arriving in the idea that all this combination and discovering the best sequencing can be a way to run towards the cure. That is our dream and I hope it’s not so far. It is the best wish that I give to our patients, to their caregivers and to all myeloma researchers.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.